Tags: Eli Lilly
Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance
China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local drugmakers.
Eli Lilly Announces New Zepbound Pricing, Broadening Patient Access via LillyDirect
Eli Lilly lowers Zepbound prices on LillyDirect to expand access and help more patients afford weight loss treatment.
New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles
Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.
Eli Lilly Announces $6.5B Texas Facility to Meet Soaring Demand for Weight-Loss Drugs
Eli Lilly announces a $6.5 billion manufacturing plant in Texas to meet rising demand for its obesity pill and other small-molecule drugs.
Latest News
Eli Lilly's weight-loss drug Mounjaro sees soaring demand in India after local launch, with clinics reporting hundreds of patient inquiries.
Eli Lilly's orforglipron, a once-daily pill, could transform the weight loss drug market with its needle-free convenience and potential market dominance.
Eli Lilly invests $27 billion in U.S. manufacturing to boost drug production and strengthen the supply chain.
Eli Lilly is suing medical spas and vendors for selling unapproved, fake weight-loss products containing their active ingredient, tirzepatide.
A new study reveals that semaglutide, a key ingredient in Ozempic and Wegovy, reduces the risk of dying from Covid-19 by 33%, [otentially boosting its market value.
Eli Lilly is launching a lower-priced version of its weight loss drug Zepbound to increase access and combat counterfeit versions.
Shares of pharmaceutical companies Novo Nordisk and Eli Lilly slid after Roche announced results from a promising early-stage trial for its proposed obesity drug.
President Joe Biden and Senator Bernie Sanders have urged Novo Nordisk and Eli Lilly to lower the prices of their popular weight loss drugs.
The FDA has approved Eli Lilly’s Alzheimer’s drug donanemab, branded as Kisunla, for early symptomatic adults, providing a new treatment option for nearly 7 million Americans affected by the disease.
The Food and Drug Administration’s advisory committee endorsed Eli Lilly’s Alzheimer’s drug, donanemab, for approval to further slow the aggression of the specific type of dementia in patients despite criticisms regarding test patient deaths during clinical trials.
















